Comparing AxoGen (AXGN) and Sunshine Heart (SSH)
AxoGen (NASDAQ: AXGN) and Sunshine Heart (NASDAQ:SSH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitabiliy, earnings, institutional ownership and valuation.
This is a summary of recent ratings and target prices for AxoGen and Sunshine Heart, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AxoGen currently has a consensus price target of $14.38, indicating a potential downside of 14.69%. Sunshine Heart has a consensus price target of $0.23, indicating a potential downside of 62.47%. Given AxoGen’s higher possible upside, research analysts clearly believe AxoGen is more favorable than Sunshine Heart.
This table compares AxoGen and Sunshine Heart’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
AxoGen has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Sunshine Heart has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500.
Valuation and Earnings
This table compares AxoGen and Sunshine Heart’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|AxoGen||$45.24 million||12.33||-$8.23 million||($0.45)||-37.44|
Sunshine Heart has higher revenue, but lower earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Sunshine Heart, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
63.7% of AxoGen shares are owned by institutional investors. 9.3% of AxoGen shares are owned by company insiders. Comparatively, 3.0% of Sunshine Heart shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
AxoGen beats Sunshine Heart on 8 of the 10 factors compared between the two stocks.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.